Immunolocalization of matrix metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma

Clinical and Experimental Metastasis

Volumn 18, Issue 6, 2000, Pages 463-470

  Lhotak S ^a   Elavathil, L J ^b   Vukmirovic S ^a   Duivenvoorden, W C M ^a   Tozer, R G ^c   Singh, G ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c CANCER CARE ONTARIO   (Canada)

Author keywords

Bone metastasis; Breast carcinoma; Histomorphometry; Human; Immunohistochemistry; MMP; TIMP

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

ARTICLE; BONE DEFECT; BONE DEVELOPMENT; BONE MARROW BIOPSY; BONE METASTASIS; BONE REMODELING; BREAST CARCINOMA; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OSTEOCLAST; OSTEOLYSIS; PATHOLOGIC FRACTURE;

BONE NEOPLASMS; BREAST NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASES; PROTEASE INHIBITORS;

EID: 0034858101     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011800919981     Document Type: Article

References (51)

1. Mechanisms of bone metastasis
2. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts
3. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer
4. Histomorphometric analysis of osteoclastic bone resorption in metastatic bone disease from various primary malignomas
5. Parathyroid hormone-related protein and bone metastases
6. Review of cellular mechanisms of tumor osteolysis
7. Interleukin-1 family expression in human breast cancer: Interleukin-1 receptor antagonist
8. Production and regulation of interleukin-11 by breast cancer cells
9. Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma
10. Interleukin-1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells
11. Activation of NF-kB is involved in the survival of osteoclasts promoted by interleukin-1
12. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts
13. Proteolytic activity of human osteoclast cathepsin
14. Complex roles of matrix metalloproteinases in tumor progression
15. Tissue inhibitors of matrix metalloproteinases in cancer
16. Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface
17. Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cystein-proteinases and matrix metalloproteinases
18. Bone cells predispose bone surfaces to resorption by exposure of mineral to osteoclastic contact
19. MMP-9/Gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes
20. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones
21. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover
22. Matrix metalloproteinases in repair
23. Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers
24. Co-culture of human breast adenocarcinoma MCF-7 cells with human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and 3 in fibroblasts
25. Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase
26. Bone metastasis in human breast and prostate cancer: Involvement of matrix metalloproteinases
27. Bone histomorphometry: Standardization of nomenclature, symbols and units (summary of proposed system)
28. Serum metalloproteinases and their inhibitors: Markers for malignant potential
29. Matrix metalloproteinases in cancer: Prognostic marker and targets for therapy
30. Matrix metalloproteinases in multiple myeloma
31. Matrix metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma
32. Levels of matrix metalloproteinase in bladder cancer correlate with tumor grade and invasion
33. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion
34. Human osteoblasts in culture synthesize collagenase and other matrix metalloproteinases in response to osteotropic hormones and cytokines
35. Production of both 92-and 72-kDa gelatinases by bone cells
36. Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV colIagenase=gelatinase B) in osteoclasts: Implications for bone resorption
37. Tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) distribution in normal and pathological human bone
38. The synthesis of collagenase, gelatinase-A (72 kDa) and -B (95 kDa), and TIMP-1 and -2 by human osteoblasts from normal and arthritic bone
39. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases
40. Tumor cell invasion inhibited by TIMP-2
41. Prognosis of gastric carcinoma revealed by the interactions between tumor cells and basement membrane
42. Differential expression of tissue inhibitor of metalloproteinase-2 by cutaneous squamous and basal cell carcinomas
43. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases
44. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence
45. Inhibition of stimulated bone resorption in vitro by TIMP-1 and TIMP-2
46. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate Ibandronate and tissue inhibitor of the matrix metalloproteinase-2
47. Tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2) stimulate osteoclastic bone resorption
48. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2)
49. Expression of metalloproteinase-13 (Collagenase-3) is induced during fracture healing in mice
50. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies
51. Stromal degradation by the malignant epithelium in pancreatic cancer and the therapeutic potential of proteolytic inhibition